Immuno-Oncology related patent filings increased in the pharmaceutical industry in Q2 2023
Notably, the number of immuno-oncology-related patent applications in the pharmaceutical industry was 182 in Q2 2023, versus 170 in the prior quarter.
The top five companies accounted for 13% of patenting activity
Analysis of patenting activity by companies shows that Immatics filed the most immuno-oncology patents within the pharmaceutical industry in Q2 2023. The company filed 7 immuno-oncology-related patents in the quarter, compared with 30 in the previous quarter. It was followed by Fred Hutchinson Cancer Research Center with 6 immuno-oncology patent filings, Bristol-Myers Squibb (4 filings), and Technion Israel Institute of Technology (3 filings) in Q2 2023.
Patenting activity was driven by the US with a 49% share of total patent filings
The largest share of immuno-oncology related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 49%, followed by China (7%) and Japan (5%). The share represented by the US was 18% higher than the 32% share it accounted for in Q1 2023.
For further understanding of GlobalData’s Immuno-Oncology – Thematic Research buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
Source link
#ImmunoOncology #related #patent #filings #increased #pharmaceutical #industry
